Original article
Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: Relationship to the development of late asthmatic responses

https://doi.org/10.1016/0091-6749(91)90013-EGet rights and content

Abstract

Inflammatory mediators have been implicated in the pathogenesis of human asthma and have been demonstrated to increase in bronchoalveolar lavage fluid during the time of the immediate asthmatic response (IAR) after allergen instillation in the lungs. However, the relationship of these mediators, measured early to the late asthmatic response (LAR), airway reactivity, and clinical asthma, is unknown. In the present study, we evaluated mediator levels in bronchoalveolar lavage fluid before and 5 minutes after allergen challenge from three subject groups: atopic subjects without asthma (N = 7), atopic subjects with asthma and without LAR ((−) LAR) (N = 6), and atopic subjects with asthma and with LAR ((+) LAR) (N = 6). subjects with asthma were differentiated into subjects with and without LARs based on at least a 15% decrease in FEV1 between 3 to 8 hours postallergen inhalation. The mediators, prostaglandin D2, thromboxane B2, leukotriene C4 (LTC4), and histamine, were measured both before and after allergen instillation. Baseline prechallenge levels were similar, except in the case of LTC4, LTC4 was detectable at baseline significantly more frequently in the atopic subjects with asthma with and without LAR when these subjects were compared to the atopic subjects without asthma (nine of 12 detectable versus one of seven detectable). In all groups, significant increases in mediator levels were observed in the groups with asthma postallergen challenge, compared to the atopic subjects without asthma. Atopic subjects with asthma and without LAR had significantly higher levels of all four mediators after challenge than atopic subjects with asthma and with LAR and atopic subjects without asthma. No correlation was found between the mediator levels and airway physiology among any of the three groups. Although atopic subjects with asthma and with LAR were more reactive to methacholine than the other two groups, the difference did not reach significance. In addition, no correlation was observed with cell counts, differentials, or proteins. It is hypothesized from these findings that multiple factors are involved in the production of an LAR. These factors most likely include mediator levels and underlying airway reactivity, with the more reactive airways requiring less mediators for bronchoconstriction to occur. This finding implies that therapeutic options in asthma should focus not only on blockage of mediator activity but also on reversal of underlying airway hyperreactivity.

References (29)

  • JJ Murray et al.

    Release of prostaglandin D2 into human airways during acute allergen challenge

    N Engl J Med

    (1986)
  • SE Wenzel et al.

    Activation of pulmonary mast cells by bronchoalveolar allergen challenge: in vivo release of histamine and tryptase in atopic subjects with and without asthma

    Am Rev Respir Dis

    (1988)
  • SE Wenzel et al.

    Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and control groups: an alteration in the ratio of bronchoconstrictive to bronchoprotective mediators

    Am Rev Respir Dis

    (1989)
  • P Rafferty et al.

    The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′-monophosphate in atopic asthma

    Am Rev Respir Dis

    (1987)
  • Cited by (163)

    • New treatments for asthma: From the pathogenic role of prostaglandin D<inf>2</inf> to the therapeutic effects of fevipiprant

      2020, Pharmacological Research
      Citation Excerpt :

      In particular, a 150-fold increase in BALF PGD2 concentration was shown a few minutes after bronchial antigen challenge with Dermatophagoides pteronyssinus [50]. In addition, airway allergen challenge in atopic asthmatics caused a significant increase in BALF PGD2 levels when compared to atopic subjects without asthma [51]. Furthermore, in comparison to healthy individuals, CRTH2-positive cells were shown to be increased within submucosal airway tissues of patients with severe asthma [52].

    • Mast cells in airway diseases and interstitial lung disease

      2016, European Journal of Pharmacology
      Citation Excerpt :

      Mast cell-derived mediators induce the classical features of the early asthmatic reaction in vivo, inducing bronchoconstriction, mucus secretion and mucosal oedema (for reviews see Bradding and Cruse (2008), Bradding et al. (2006), Brightling et al. (2003a) and Moiseeva and Bradding (2011)). For example, several studies have identified an increase in histamine, prostaglandin D2 (PGD2) and leukotriene C4 (LTC4) in the BAL fluid of asthma subjects following bronchial allergen challenge (Casale et al., 1987; Liu et al., 1991; Murray et al., 1986; Sedgwick et al., 1991; Wenzel et al., 1988, 1990, 1991) and that the early asthmatic reaction is significantly alleviated with the administration of potent selective inhibitors of histamine, LTC4 and to a lesser extent PGD2 (Beasley et al., 1987; Curzen et al., 1987; Findlay et al., 1992; Rafferty et al., 1987; Taylor et al., 1991). These mediators are most likely derived from mast cells in the bronchial mucosa because histamine, PGD2 and LTC4 are all released from human lung mast cells in vitro with remarkably similar kinetics to the allergen challenge studies (Schleimer et al., 1986).

    • Biology of Mast Cells and Their Mediators

      2014, Middleton's Allergy: Principles and Practice: Eighth Edition
    View all citing articles on Scopus

    Supported by National Institutes of Health Grants NRSA HL-07433, HL-36577, and HL-34303.

    From the Departments of Medicine and Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colo.

    ∗∗

    From the Webb-Waring Lung Institute and Cardiovascular Pulmonary Research Department, University of Colorado School of Medicine, Denver, Colo.

    View full text